Review existing health technology assessments

To explore what potential effectiveness challenges may be relevant to a particular medicine, it may be helpful to examine previous health technology assessments (HTA) reports for similar medicines and/or for other medicines on similar conditions.

It is also useful to consider how the generation of real-world evidence may change reimbursement decisions. The following reviews at two HTA agencies examined whether reimbursement decisions by the respective agency changed, following the generation of real-world evidence.

  • Zorginstitut Netherlands (ZIN), the national HTA agency in the Netherlands – see here
  • Haute Autorité de Santé (HAS), the national HTA agency in France – see here